| Статус: | Recruiting |
| Фаза: | Phase 1/Phase 2 |
| Начало: | 1 марта 2021 г. |
| Окончание: | 1 октября 2024 г. |
| Описание: | Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory classical Hodgkin lymphoma. A PET-adapted regimen of Nivo combined with ICE as first salvage therapy was shown to induce high response rates and favorable progression-free survival as a bridge to autologous stem cell transplantation, allowing to omit salvage chemotherapy in a substantial proportion of r\r cHL patients. This study evaluates the safety and efficacy of PET-adapted treatment of nivolumab at the fixed dose of 40 mg in combination with ifosfamide, carboplatin, and etoposide (NICE-40) in patients with relapsed/refractory Hodgkin Lymphoma. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | N/A |
| Начало: | 1 февраля 2020 г. |
| Окончание: | 1 июня 2021 г. |
| Описание: | Nutritional therapy implementation in hematopoietic stem cell transplantation (HSCT) have undergone changes recently due to new conditioning regimen and graft versus disease prophylaxis, novel enteral and parenteral nutrition solutions: the value of enteral nutrition is increasing, the indications for parenteral nutrition are becoming more strict. The study aims to identify the role of parenteral nutrition in the context of rapidly changing supportive care approaches in HSCT |
| смотреть на ClinicalTrials.gov |